



Innovations that work.™

ACN 109 200 900

ASX ANNOUNCEMENT

30 April 2026

MARCH 2026 QUARTERLY ACTIVITIES REPORT

Eden Innovations Ltd (ASX:EDE) (“Eden” or “the Company”) is pleased to provide the following activities report for the quarter ended 31 March 2026.

HIGHLIGHTS

EdenCrete Americas ‘Ready Mix Concrete Plant’ Expansion:

- Amrize (formerly Holcim US/Canada) requests installation of EdenCrete Pz7 bulk storage tanks and dispensing equipment at 5 more Colorado plants - taking total to 10 plants of 300 in their network. Significant scope for further rollout across North American market.
- New Channel partner installations with the USA-wide Quikrete group

EdenShield® Launched:

- A new dedicated Defence, Military and Infrastructure division launched to commercialise Eden’s product suite across critical infrastructure and national security applications.
- Ms Julie Bown appointed as Strategic Advisor – Defence, bringing 30 years’ experience in the defence and aerospace sectors and deep relationships across the Australian defence ecosystem, to progress commercialisation pathways for EdenShield® products.

OptiBlend US Momentum: Continued strong order intake from range of customers including US data centre operators; active US quotations pipeline of approx. US\$4.33 million (A\$6.0 million).

New Managing Director: Appointment of Dr Allan Godsk Larsen as Managing Director to lead the next phase of global growth.

Balance Sheet Reset and Debt / Cost Reduction: Full elimination of iBorrow debt — saving A\$1m+ p.a. in interest — via a A\$2.2m strategic investment from 7 Enterprises Pty Ltd, completing a total debt reduction of ~A\$16m since 30 June 2025.

New R&D Initiative: Investment in new R&D equipment to expand carbon nanotube concrete technology into AI and cloud data centre applications, targeting heat dissipation and electromagnetic shielding performance.

Eden India: EdenCrete CRRI (Concrete Road Repair Institute) trials commenced in fourth week of April, 2026 following unexpected delays unrelated to EdenCrete.

\$4 Million Placement: Post quarter-end, Eden announced a \$4m institution-led placement at \$0.18 per share (being a 41% premium to the 15-day VWAP at the time). The placement was cornerstoned by L1 Capital Global Opportunities Master Fund and lead managed by Oakley Capital Partners Pty Limited, with Bell Potter Securities as Co-Manager.

SALES AND ACTIVITIES DURING Q3 FY26

EdenCrete® Products Highlights


Ready Mix Concrete Plant Growth and North American Expansion

During the quarter, Amrize, the largest cement and building materials supplier in North America, requested that Eden supply bulk EdenCrete Pz7 storage tanks and dispensing systems to support regular sales of Pz7-enriched concrete mixes at five additional ready-mix concrete (“RMC”) plants in Colorado. This takes the total number of Amrize plants using EdenCrete Pz7 to 10 out of a regional network of 300 plants — representing significant scope for further roll-out across the North American market through this network alone.

Further, Eden US completed EdenCrete Pz7 bulk storage tank and dispensing equipment installations at 2 Quikrete RMC plants in Colorado and is preparing equivalent installations at 2 other plants within the US-wide Quikrete group.

Quikrete is one of the largest producers of packaged concrete products in the US and a significant ready mix concrete operator, which represents a significant new channel partner for Eden's Pz7 product line.

Management expects a significant rise in total EdenCrete Pz7 sales over the coming 12-24 months as orders are received to supply the existing and new customer plants.



South America and International Markets

Eden US has been supplying EdenCrete Pz7 to enrich standard low-carbon concrete mixes at nine Holcim plants in Ecuador since 2024. Total cumulative purchases from Holcim Ecuador have now exceeded US\$697,830, with the most recent order (received December 2025) totalling US\$341,850 — representing 49% of all Holcim Ecuador purchases to date. Annual sales to Holcim Ecuador alone are estimated to potentially reach A\$1.2 million.

Holcim has also commenced rolling out EdenCrete Pz7 dispensing systems at plants owned by its subsidiaries in the US and Ecuador, while continuing extended trials of EdenCrete Pz and EdenCrete Pz7 in Canada, Mexico, the UK, and France.

Further, as reported in January 2026, the Company's subsidiary, Eden India are presently undertaking trials to extend earlier encouraging preliminary trials with the Concrete Road Repair Institute (CRRI), an Indian Federal Government agency based in Delhi, with the new trials being focused on two specific concrete grades that are widely used in Indian government infrastructure projects. Eden is optimistic that these current trials will deliver sufficient concrete mix performance improvements, which would lead to a significant increase in sales of Pz7 in India.

EdenShield® Division Launch

During the quarter, Eden was pleased to announce the establishment of **EdenShield®**, a new business division dedicated to commercialising the Company's existing and pipeline technologies into the defence, military, and critical infrastructure sectors. The division has been formed in response to increasing global geopolitical tensions and growing government focus on infrastructure resilience, energy security and defence capability. EdenShield® will target a broad range of strategic assets including defence installations, data centres, ports, airports, hospitals, energy systems, and transport infrastructure.

EdenShield® will initially market two established Eden technologies into these sectors. EdenCrete®, the Company's carbon nanotube (CNT) enriched concrete additive, offers Ultra-High Performance Concrete (UHPC) with significant blast-resistance, electromagnetic pulse (EMP) and radio-wave shielding properties, and superior thermal durability — characteristics well suited to hardened and mission-critical infrastructure such as bunkers, hangars, runways, and military storage facilities. OptiBlend®, the Company's dual-fuel system, enables diesel generators to operate on a blend of diesel and natural gas, extending backup power capability by up to 150% while materially reducing fuel costs — a compelling proposition for facilities requiring sustained operational continuity.

Looking ahead, EdenShield® will also drive development and commercialisation of next-generation CNT-based materials, including EdenPlast® high-strength lightweight polymers suited to drone and UAV applications, advanced protective coatings, and Radiation-Absorbent Materials (RAM) for defence and aerospace use. Eden's technologies are uniquely positioned to reduce infrastructure damage from blast events, extreme weather, and thermal stress; mitigate electromagnetic and radiation-related risks; and extend the operational capability of essential systems during disruptions. While these technologies cannot eliminate such risks entirely, they offer practical and scalable solutions to materially reduce their impact and support national security and civil defence objectives.

Research & Development and AI Data Centre Applications

During the quarter Eden announced an investment in new R&D equipment to expand the application of its carbon nanotube-enriched concrete technology into the specialised requirements of rapidly growing AI and cloud data centres. The Company's research will focus on leveraging CNT concrete's inherent properties — including enhanced heat dissipation and electromagnetic shielding — to serve data centre infrastructure requirements.

Leveraging its established carbon nanotube (“CNT”) production capability, EdenCrete®'s track record, and existing US regulatory approvals, Eden is positioning to tap the surging global data centre construction pipeline. Analysts estimate global data centre investment could exceed US\$1 trillion by 2035, driven by AI and cloud computing demand. Eden US is already active in the data-centre-sector through its OptiBlend technology (see detail below).

Indian EdenCrete Trials

A significant trial of EdenCrete admixtures by CRRI (Concrete Road Repair Institute) in a medium strength concrete mix, commenced in fourth week of April 2026, following a series of unexpected delays, all unrelated to EdenCrete.

The trials involve testing a range of performance characteristics of EdenCretePz-enriched concrete compared with the same concrete mix without the added EdenCretePz.

If the trials are successful, it will be an important initial milestone in Eden's efforts to have its EdenCrete admixture included in concrete used in India for a wide range of potential applications including highways and roads, bridges, infrastructure and high-rise buildings.

A positive result may well lead to follow-up trials of both the same concrete mix and also higher strength concrete mixes.

Whilst these trials have been delayed, they are an extremely important first step towards having EdenCrete used in the huge Indian infrastructure and construction markets.

OptiBlend Highlights

Overview

OptiBlend is Eden's patented retrofit dual-fuel technology that allows conventional diesel engines to operate primarily on natural gas — up to a 65% natural gas / 35% diesel mix — without modification to the engine or existing diesel fuel system. This reduces fuel costs, lowers CO₂ and diesel particulate emissions, and extends backup generator run-time by up to 300%.

The technology is gaining strong commercial traction with US data centre operators seeking to reduce operating costs and emissions while improving energy security.

OptiBlend addresses a clear operational need for backup power operators — lower fuel costs, reduced emissions, and a dramatic increase in generator runtime — without requiring any modification to existing engines or diesel fuel infrastructure.

US Sales & Pipeline

Active OptiBlend quotations in the US currently stand at approximately USD4.33 million (A\$6.0 million), underpinned by confirmed purchase orders of approximately US\$456k (A\$633k). Order momentum accelerated through the quarter, particularly from data centre clients, following the delivery and installation of multiple units in Q2 FY2026 as previously reported.

In the first 9 months of the current financial year (FY2026) to 31 March 2026, the total US OptiBlend revenue exceeded US\$1.18 million (AUD\$1.69 million), an increase of over 65% on the total annual US OptiBlend revenue generated in FY2025.

Management and Corporate Updates

Strategic investment, iBorrow debt and servicing costs eliminated

In January 2026, Eden secured a \$2.2 million convertible note from strategic shareholder, 7 Enterprises Pty Ltd, with proceeds used to fully repay the remaining \$2.7 million balance of the Company's iBorrow LP loan. This loan was converted to shares in February 2026, increasing 7 Enterprises Pty Ltd shareholding in Eden to 6.1%.

Since 30 June 2025, the Company has now fully repaid the iBorrow loan of \$8.7 million — a facility that previously cost in excess of \$1.0 million per annum in interest and associated debt servicing costs. The transaction materially strengthens Eden's cash flow profile and accelerates its pathway to cash-flow-positive operations.

To reach debt free status, Eden has also reached agreement with its remaining loan holders Arkenstone Pty Ltd and March Bells Pty Ltd (related to directors Greg Solomon and Doug Solomon) and separately with its directors to settle outstanding debts and accrued director fees of \$1,839,141 in aggregate through share issues at the same price as the convertible debt (see table below) , subject to receiving shareholder approval at a meeting planned to be held in June, with a notice of meeting to be dispatched in the coming weeks.

Liability	Amount to settle	Share issue to settle
Outstanding loans (including accrued interest) from Arkenstone Pty Ltd and March Bells Pty Ltd	\$1,185,000	12,473,684
Accrued director fees to Greg Solomon from 1 October 2023 to 31 January 2026, net of tax and superannuation to be paid by the Company	\$538,261	5,665,905
Accrued director fees to Doug Solomon from 1 October 2023 to 31 January 2026, net of tax and superannuation to be paid by the Company	\$115,880	1,219,789

Funding

Post quarter-end, Eden announced an institutionally-led placement to raise \$4.05 million at \$0.18 per share, being a 41% premium to the 15-day VWAP. The placement was led by Oakley Capital Partners and Bell Potter Securities, and was cornerstoned by L1 Capital Global Opportunities Master Fund.

At the end of the quarter, the Company had \$2.5 million cash at bank. The Company also notes that it has approximately 237 million options on issue, which are currently in-the-money based on the ASX closing price of Company shares on 29 April 2026, comprising the following option classes:

Option Class	Number on issue	Expiry Date	Exercise Price
EDEO	146,318,886	8 Sep 2027	\$0.07
EDEOD	29,355,042	11 Sep 2026	\$0.18
EDEAG	61,750,000	11 Aug 2027	\$0.08
Total:	237,423,928		

If all of these options were to be exercised, this would result in an additional cash injection of up to approximately \$20.46 million to the Company. Although there is no guarantee that the Company's share price will remain above the exercise price of some or all of these option classes prior to the relevant expiry date.

Appointment of Managing Director to drive growth

Eden was pleased to confirm the appointment of Dr Allan Godsk Larsen as Managing Director during the quarter. Dr Larsen has been the Chief Scientist at Eden for 8 years, and in that time invented the EdenCretePz and EdenCretePz7 products which are leading growth of sales of the EdenCrete product range.

Mr Larsen's appointment reflects the Company's intention to accelerate its next phase of global growth following the successful completion of the balance sheet restructuring program.

Management is also considering a number of further key hires, including within the business development team.

Mead Way, Littleton, Colorado, US Property

Eden continues to market for sale its free owned property in Littleton, Colorado. In 2023, this property had an appraised value of \$2,600,000. Sale of this property will further boost the Company's working capital and cash reserves to be applied towards growth.

Group Outlook and Priorities

With Eden's recent recapitalisation and substantial debt reduction, including elimination of its high-cost iBorrow debt, Eden enters Q4 FY2026 with a materially de-risked balance sheet and a motivated management & sales team now well positioned to rapidly commercialise the EdenCrete and OptiBlend technology lines.

Key priorities for the remainder of FY2026 include:

- Scaling EdenCrete Pz7 sales across Amrize, Quikrete, and Holcim ready mix plant networks in the Americas;
- prioritise securing initial commercial engagements and pilot project opportunities for EdenShield®, to build a pipeline of defence and critical infrastructure contracts while progressing development of its next-generation CNT-based materials;
- Supporting the incoming Managing Director's global growth mandate, including expanding the business development team;
- Expanding OptiBlend order flow from US data centre operators and converting the US\$4.33 million active quotation pipeline;
- Advancing carbon nanotube concrete R&D for applications to AI and cloud data centre infrastructure;
- Progressing EdenCrete trials and partnerships in Canada, Mexico, the UK, France, and Indonesia; and
- Continue to advance towards the Group's target to reach positive operating cash flow.

Description of payments to related parties of the entity and their associates (LR 5.3.5)

The Company paid \$88k for Director fees, including \$52k to Mr Allan Larsen, for executive consulting services.

ENDS



Gregory H Solomon

Executive Chairman

This report was authorised by the Board of the Company.

Forward Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of the Company are, or may be, forward looking statements. Such statements relate to future events and expectations and as such, involve known and unknown risks and uncertainties. Actual results and developments may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors. The past performance of the Company is no guarantee of future performance.

None of the Company's directors, officers, employees, agents or contractors makes any representation or warranty (either express or implied) as to the accuracy or likelihood of fulfilment of any forward-looking statement, or any events or results expressed or implied in any forward-looking statement, except to the extent required by law. You are cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statements in this announcement reflect views held only as at the date of this announcement.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Eden Innovations Ltd

ABN

58 109 200 900

Quarter ended ("current quarter")

31 March 2026

Consolidated statement of cash flows		Current Quarter \$A'000	Year to Date (9 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	577	1,837
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(694)	(1,712)
	(c) advertising and marketing	-	(31)
	(d) leased assets	-	-
	(e) staff costs	(637)	(1,836)
	(f) administration and corporate costs	(286)	(836)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	5	12
1.5	Interest and other costs of finance paid	(47)	(563)
1.6	Income taxes paid (India)	-	(49)
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	(1,082)	(3,205)
2.	Cash flows from investing activities		
2.1	Payments to acquire or for:	-	-
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	(2)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current Quarter \$A'000	Year to Date (9 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	7,019
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	(591)
2.6	Net cash from / (used in) investing activities	-	6,426
3. Cash flows from financing activities			
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	5,163
3.2	Proceeds from issue of convertible debt securities	2,200	2,200
3.3	Proceeds from exercise of options	331	331
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(368)
3.5	Proceeds from borrowings	-	239
3.6	Repayment of borrowings	(2,397)	(8,569)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	134	(1,003)
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period *	3,549	412
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,082)	(3,205)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	6,426
4.4	Net cash from / (used in) financing activities (item 3.10 above)	134	(1,003)
4.5	Effect of movement in exchange rates on cash held	(35)	(64)
4.6	Cash and cash equivalents at end of period	2,566	2,566

Consolidated statement of cash flows	Current Quarter \$A'000	Year to Date (9 months) \$A'000
* Adjusted opening cash from 31 Dec 25 report to reduce by \$121k to remove restricted class reclassified as receivable		

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current Quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	2,566	3,227
5.2 Call deposits	-	322
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,566	3,549

6. Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1 Aggregate amount of payments to related parties and their associates included in item 1	88
6.2 Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>	
Fees paid to non-executive directors and the management director as a consultant.	

7. Financing facilities <i>Note: the term 'facility' includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at Quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	1,172	4,505
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	1,172	4,505
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
At call, unsecured loan from Arkenstone Pty Ltd and March Bells Pty Ltd accruing interest at 9.97% pa.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(1,082)
8.2 Cash and cash equivalents at quarter end (item 4.6)	2,566
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	2,566
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	2.3
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 April 2026

Authorised by: Brett Tucker, Company Secretary
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.